)
)
)
IsletRegen
IsletRegen, LLC (‘IsletRegen’) is a Virginia-based company that is revolutionizing the treatment of autoimmune diseases by combining first-in-class cytotoxic T-cell depletion, suppression of human HLA Class I molecule expression and human endocrine cell regeneration in a single agonist. The drug is RegenpepTM, a newly patented synthetic peptide agonist. For proof of principle, IsletRegen's current focus is on Type 1 Diabetes and Arthritis, with studies on Alzheimer's disease underway. RegenpepTM is the first and only agonist capable both blocking early development of autoimmunity and restoring natural insulin production through pancreatic beta cell regeneration.
Address
CharlottesvilleVirginia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)